Mario Songane

Dr. Mario Songane


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2017 in International Journal of Health Economics and Management
Verified
Journal Article
Closed access
PDF file
MSMario Songane
Mario Songane

26 May 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMario Songane
Mario Songane
CMCélia C Magaia
Célia C Magaia
ACAleny Couto
Aleny Couto
NDNataniel Dengo
Nataniel Dengo
ACAbdul R Cassamo
Abdul R Cassamo
SMSushant S Mukherjee
Sushant S Mukherjee
Background: In Mozambique, 38.7% of women and 60.4% of men ages 15–59 years old living with HIV do not know their HIV status. A pilot home-based HIV counseling and testing program based on index cases in the community was implemented in eight districts in Gaza province (Mozambique). The pilot targeted the sexual partners, biological children under 14 years old living in the same household, and parents (for pediatric cases) of people living with HIV. The study aimed to estimate the cost-efficiency and effectiveness of community index testing and compare the HIV testing outputs with facility-based testing.Methods: Community index testing costs included the following categories: human resources, HIV rapid tests, travel and transportation for supervision and home visits, training, supplies and consumables, and review and coordination meetings. Costs were estimated from a health systems perspective using a micro-costing approach. All project costs were incurred between October 2017 and September 2018 and converted to U.S. dollars ($) using the prevailing exchange rate. We estimated the cost per individual tested, per new HIV diagnosis, and per infection averted.Results: A total of 91,411 individuals were tested for HIV through community index testing, of which 7,011 were newly diagnosed with HIV. Human resources (52%), purchase of HIV rapid tests (28%) and supplies (8%) were the major cost drivers. The cost per individual tested was $5.82, per new HIV diagnosis was $65.32, and per infection averted per year was $1,813. Furthermore, the community index testing approach proportionally tested more males (53%) than facility-based testing (27%).Conclusion: These data suggest that expansion of the community index case approach may be an effective and efficient strategy to increase the identification of previously undiagnosed HIV-positive individuals, particularly males.

6 September 2023 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
NMNyashadzaishe Nyashadzaishe Mafirakureva
Nyashadzaishe Nyashadzaishe Mafirakureva
SMSushant Mukherjee
Sushant Mukherjee
MSMikhael de Souza
Mikhael de Souza
CKCassandra Kelly-Cirino
Cassandra Kelly-Cirino
MSMario Songane
Mario Songane
PDPeter J. Dodd
Peter J. Dodd
Background: Over 1 million children aged 0 to 14 years were estimated to develop tuberculosis in 2021, resulting in over 200,000 deaths. Practical interventions are urgently needed to improve diagnosis and antituberculosis treatment (ATT) initiation in children aged 0 to 14 years and to increase coverage of tuberculosis preventive therapy (TPT) in children at high risk of developing tuberculosis disease. The multicountry CaP-TB intervention scaled up facility-based intensified case finding and strengthened household contact management and TPT provision at HIV clinics. To add to the limited health-economic evidence on interventions to improve ATT and TPT in children, we evaluated the cost-effectiveness of the CaP-TB intervention. Methods and findings: We analysed clinic-level pre/post data to quantify the impact of the CaP-TB intervention on ATT and TPT initiation across 9 sub-Saharan African countries. Data on tuberculosis diagnosis and ATT/TPT initiation counts with corresponding follow-up time were available for 146 sites across the 9 countries prior to and post project implementation, stratified by 0 to 4 and 5 to 14 year age-groups. Preintervention data were retrospectively collected from facility registers for a 12-month period, and intervention data were prospectively collected from December 2018 to June 2021 using project-specific forms. Bayesian generalised linear mixed-effects models were used to estimate country-level rate ratios for tuberculosis diagnosis and ATT/TPT initiation. We analysed project expenditure and cascade data to determine unit costs of intervention components and used mathematical modelling to project health impact, health system costs, and cost-effectiveness. Overall, ATT and TPT initiation increased, with country-level incidence rate ratios varying between 0.8 (95% uncertainty interval [UI], 0.7 to 1.0) and 2.9 (95% UI, 2.3 to 3.6) for ATT and between 1.6 (95% UI, 1.5 to 1.8) and 9.8 (95% UI, 8.1 to 11.8) for TPT. We projected that for every 100 children starting either ATT or TPT at baseline, the intervention package translated to between 1 (95% UI, −1 to 3) and 38 (95% UI, 24 to 58) deaths averted, with a median incremental cost-effectiveness ratio (ICER) of US$634 per disability-adjusted life year (DALY) averted. ICERs ranged between US$135/DALY averted in Democratic of the Congo and US$6,804/DALY averted in Cameroon. The main limitation of our study is that the impact is based on pre/post comparisons, which could be confounded. Conclusions: In most countries, the CaP-TB intervention package improved tuberculosis treatment and prevention services for children aged under 15 years, but large variation in estimated impact and ICERs highlights the importance of local context. Trial registration: This evaluation is part of the TIPPI study, registered with ClinicalTrials.gov (NCT03948698).

11 January 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMario Songane
Mario Songane
VGVolker Grossmann
Volker Grossmann
Human papillomavirus (HPV) is responsible for almost all of the 570,000 new cases of cervical cancer and approximately 311,000 deaths per year. HPV vaccination is an integral component of the World Health Organization’s (WHO) global strategy to fight the disease. However, high vaccine prices enforced through patent protection are limiting vaccine expansion, particularly in low- and middle-income countries. By limiting market power, patent buyouts could reduce vaccine prices and raise HPV vaccination rates while keeping innovation incentives. We estimate the global patent buyout price as the present discounted value (PDV) of the future profit stream over the remaining patent length for Merck’s HPV vaccines (Gardasil-4 and 9), which hold 87% of the global HPV vaccine market, in the range of US$ 15.6–27.7 billion (in 2018 US$). The estimated PDV of the profit stream since market introduction amounts to US$ 17.8–42.8 billion and the estimated R&D cost to US$ 1.05–1.21 billion. Thus, we arrive at a ratio of R&D costs to the patent value of the order of 2.5–6.8%. We relate this figure to typical estimates of the probability of success (POS) for clinical trials of vaccines to discuss if patent protection provides Merck with extraordinarily strong price setting power.

21 January 2025 in BMJ Public Health
Verified
Journal Article
Open access
PDF file
MSMario Songane
Mario Songane
Boris Tchakounte YounguiBoris Tchakounte Youngui
Boris Tchakounte Youngui
AMAlbert Mambo
Albert Mambo
GBGeorges Bonabe
Georges Bonabe
TDTatiana KATCHO DJIKEUSSI
Tatiana KATCHO DJIKEUSSI
Boris Kevin TchoungaBoris Kevin Tchounga
Boris Kevin Tchounga
Introduction: SARS-CoV-2 contact tracing in Cameroon has been done manually using paper forms and phone calls. However, there were reports of inaccurate contact details, resulting in delays in identifying and testing contacts. A recently introduced digital contact-tracing module using the Mamal Pro app automatically sends SMS messages to notify all reported contacts and the district unit. We assessed the total costs, cost per contact reached, tested and found SARS-CoV-2-positive for both manual (standard of care, SOC) and app-based (intervention, ITV) contact-tracing approaches. Methods: A cluster randomised trial comparing the SOC and ITV was implemented across eight health districts in Cameroon between October 2022 and March 2023. The cost per contact reached, tested and found SARS-CoV-2-positive was calculated by dividing the total cost of each approach by the number of contacts reached, tested and found SARS-CoV-2-positive, respectively. We also estimated the minimum number of SARS-CoV-2-positive contacts that need to be found and the maximum total cost of ITV in order to equal the SOC’s cost per SARS-CoV-2-positive contact. Results: In the SOC, of 849 contacts identified, 463, 123 and 5 were reached, tested and found SARS-CoV-2-positive, respectively. In the ITV, of the 854 contacts identified, 801, 182 and 4 were reached, tested and found SARS-CoV-2-positive, respectively. In the SOC, the cost per contact reached was US$70, per contact tested was US$262 and per SARS-CoV-2-positive contact was US$6437. In the ITV, the cost per contact reached was US$48, per contact tested was US$210 and per SARS-CoV-2-positive contact was US$9573. The minimum number of SARS-CoV-2-positive contacts the ITV needs to find and the maximum total cost of the ITV to equal the SOC’s cost per SARS-CoV-2-positive were 6 and US$25 748, respectively. Conclusion: Using the Mamal Pro digital contact tracing app module increased the number of clients’ contacts reached and tested for SARS-CoV-2 and reduced the cost per contact reached and tested. Trial registration number: NCT05684887.

1 April 2025 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
RMRose Masaba
Rose Masaba
SSStephen Siamba
Stephen Siamba
HHHeather J. Hoffman
Heather J. Hoffman
EOEdyth Osire
Edyth Osire
NKNjoki Kimani
Njoki Kimani
LDLise Denoeud-Ndam
Lise Denoeud-Ndam
: Mass testing with antigen-detecting rapid diagnostic tests (Ag-RDT), including testing of asymptomatic individuals, is expected to improve the identification of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections. Mass testing was offered at large gatherings to determine the SARS-CoV-2 case detection rate and the acceptance and cost of implementing this community testing strategy. In 49 high-attendance venues in Kiambu County, Kenya, from June to September 2022, individuals 2 years and older were offered coronavirus disease 2019 (COVID-19) testing, vaccination, and participation in a survey. Polymerase chain reaction (PCR) testing and genome sequencing were conducted for those testing positive by Ag-RDT and those testing negative but with COVID-19 symptoms. Costs were collected from financial records, budgets, and invoices and estimated from a health systems perspective using a micro-costing method. A total of 4,062 individuals were offered testing. The testing acceptance was 3,174/4,062 (78.1%). The case detection rate was 34/3,174 (1.07%; 95% CI: 0.7–1.4%), and 11/34 (32%) of the positives were asymptomatic. The PCR results were available for 27 Ag-RDT‒positive participants and 14 Ag-RDT‒negative participants with SARS-CoV-2 symptoms and were positive in 24/27 (88.9%) and 4/14 (28.6%), respectively. Circulating variants were identified in 11 participants. Community mobilization was the major cost driver (26%) followed by purchase of SARS-CoV-2 Ag-RDTs (20.5%). The cost per individual tested was USD $15.89, and the cost per individual tested positive for SARS-CoV-2 was USD $1,484. The study demonstrates that SARS-CoV-2 Ag-RDTs could be used for identification of SARS-CoV-2 infections in both symptomatic and asymptomatic individuals at mass gatherings.